Federal Register / Vol. 65, No. 121 / Thursday, June 22, 2000 / Notices 38859

3095. General information concerning

the Commission may also be obtained

by accessing its Internet server (http://

www.usitc.gov). Hearing-impaired

persons are advised that information on

the matter can be obtained by contacting

the Commission’s TDD terminal on 202–

205–1810.

SUPPLEMENTARY INFORMATION: This

investigation was instituted on June 17,

2000, based on a complaint by Moen

Incorporated of Ohio. 64 FR 32522.

Moen’s complaint alleged unfair acts in

violation of section 337 in the

importation and sale of certain twohandle centerset faucets and

escutcheons, and components thereof.

The complaint alleged that five

respondents had infringed a U.S. design

patent held by complainant Moen. The

five respondents named in the

investigation were Foremost

International Trading, Inc. of East

Hanover, New Jersey (Foremost); Chung

Cheng Faucet Co. Ltd. of Taiwan (Chung

Cheng); Hometek International Group of

Illinois (Hometek); Stuhlbarg

International Sales Company Inc. d.b.a.

Sisco, Inc. of Rancho Dominguez,

California (Sisco); and Lota

International Co. Ltd. of the People’s

Republic of China (Lota).

On October 6, 1999, the Commission

determined not to review an ID

terminating the investigation as to

Hometek on the basis of a consent order.

On December 29, 1999, the Commission

issued a notice that an ID granting

complainant’s motion for partial

summary determination that it had

satisfied the economic prong of the

domestic industry requirement had

become the determination of the

Commission. An evidentiary hearing

before the ALJ was held December 13–

15, 1999, with complainant,

respondents Foremost and Chung

Cheng, and the Commission

investigative attorney (IA) participating.

On February 1, 2000, the Commission

determined not to review an ID

terminating the investigation as to

respondents Sisco and Lota on the basis

of consent orders.

On March 17, 2000, the ALJ issued his

final ID, finding a violation of section

337 by Foremost and Chung Cheng, the

two remaining respondents. The ALJ

also issued his recommendations on

remedy and bonding. The ALJ

recommended that the Commission

issue a general exclusion order directing

that faucets that infringe the ‘466 patent

be excluded from entry into the United

States. He also recommended a 264

percent bond during the period of

Presidential review.

No party filed a petition for review of

the ID.

After examining the record in the

investigation, the Commission

determined not to review the ID, and

requested written submissions on

remedy, the public interest, and

bonding.

The Commission received written

submissions from Moen and the IA that

addressed the form of remedy, if any,

that should be ordered, the effect of a

remedy on the public interest, and the

amount of the bond that should be

imposed during the 60-day Presidential

review period.

Having reviewed the record in this

investigation, including the written

submissions of the parties, the

Commission determined that the

appropriate form of relief is a general

exclusion order prohibiting the

unlicensed entry for consumption of

two-handle centerset faucets and

escutcheons that infringe U.S. Letters

Patent Des. 347,466. The Commission

also determined that the public interest

factors enumerated in subsection (d) of

section 337 do not preclude the

issuance of the aforementioned general

exclusion order, and that the bond

during the Presidential review period

shall be in the amount of 264 percent of

the entered value of the articles in

question.

Copies of the Commission’s orders,

the public version of the ID, and all

other nonconfidential documents filed

in connection with this investigation,

are or will be available for inspection

during official business hours (8:45 a.m.

to 5:15 p.m.) in the Office of the

Secretary, U.S. International Trade

Commission, 500 E Street SW.,

Washington, DC 20436, telephone 202–

205–2000.

This action is taken under the

authority of section 337 of the Tariff Act

of 1930, 19 U.S.C. 1337, and sections

210.45–210.51 of the Commission’s

Rules of Practice and Procedure, 19 CFR

210.45–210.51.

Issued: June 19, 2000.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 00–15820 Filed 6–21–00; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated February 11, 2000,

and published in the Federal Register

on February 22, 2000, (65 FR 35), B.I.

Chemicals, Inc., 2820 N. Normandy

Drive, Petersburg, Virginia 23805, made

application by letter to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

methadone-intermediate (9254), a basic

class of controlled substance listed in

Schedule II.

The firms plans to bulk manufacture

methadone-intermediate for formulation

into finished pharmaceuticals.

DEA has considered the factors in title

21, United States Code, section 823(a)

and determined that the registration of

B.I. Chemicals, Inc. to manufacture

methadone-intermediate is consistent

with the public interest at this time.

DEA has investigated B.I. Chemicals,

Inc. on a regular basis to ensure that the

company’s continued registration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security systems, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: June 7, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–15691 Filed 6–21–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated October 8, 1999, and

published in the Federal Register on

October 18, 1999, (64 FR 56226), Chirex

Technology Center, Inc., DBA Chirex

Cauldron, 383 Phoenixville Pike,

Malvern, Pennsylvania 19355, made

application by renewal to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

amphetamine (1100), a basic class of

controlled substance listed in Schedule

II.

The firm plans to bulk manufacture

amphetamine and its salts for product

development.

38860 Federal Register / Vol. 65, No. 121 / Thursday, June 22, 2000 / Notices

DEA has considered the factors in title

21, United States Code, section 823(a)

and determined that the registration of

Chirex Technology Center, Inc., DBA

Chirex Cauldron to manufacture

amphetamine is consistent with the

public interest at this time. DEA has

investigated the firm to ensure that the

company’s registration is consistent

with the public interest. The

investigation included inspection and

testing of the company’s physical

security systems, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: June 7, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–15688 Filed 6–21–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on March 30, 2000, Radian

International LLC, 14050 Summit Drive

#121, P.O. Box 201088, Austin, Texas

78720–1088, made application by

renewal to the Drug Enforcement

Administration to be registered as an

importer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) .......................... I

Drug Schedule

Methcathinone (1237) .................. I

N-Ethylamphetamine (1475) ........ I

gamma hydroxybutyric acid

(2010).

I

Ibogaine (7260) ............................ I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) .......................... I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine (7400).I

3,4-Methylenedioxy-N-ethylamphetamine (7404).I

3,4-Methylenedioxymethamphetamine (7405).I

4-Methoxyamphetamine (7411) ... I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Ethorphine (except HC1) (9056) .. I

Heroin (9200) ............................... I

Pholcodine (9314) ........................ I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Meperidine (9230) ........................ II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

levo-alphacetylmethadol (9648) ... II

Oxymorphone (9652) ................... II

The firm plans to import small

quantities of the listed controlled

substances for the manufacture of

analytical reference standards.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than July 24, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: June 8, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–15687 Filed 6–21–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of title

21 of the Code of Federal Regulations

(CFR), this is notice that on December

10, 1999, Salsbury Chemicals, Inc., 1205

11th Street, Charles City, Iowa 50616–

3466, made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

amphetamine (1100) and by letter dated

March 14, 2000, for registration to bulk

manufacture methylphenidate (1724),

basic classes of controlled substances

listed in Schedule II.

The firm plans to manufacture

amphetamine and methylphenidate for

distribution as bulk product.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than August

21, 2000.